

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-230) GEBASXTUREV

PRONUNCIATION ge ba" sax too' rev

THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAME

Human coxsackievirus A21

PHARMACOLOGICAL ACTION

As an oncolytic virus, V937 therapeutic efficacy relies on its ability to exploit biochemical differences between normal and transformed cells as well as activating the host antitumor immunity. V937 achieves this through a combination of 1) attaching to cell surface receptors to gain entry into neoplastic cells by binding to ICAM-1 (CD54) and DAF-1 (CD55) which are overexpressed on many tumor types, and 2) by capitalizing on the replicative permissiveness inherent to tumor cells.

SPONSOR Merck, Sharp & Dohme Corporation

TRADE NAME None yet

CODE DESIGNATIONS V937

CAS REGISTRY NUMBER 2122169-83-7

UNII 4B57CWT710

WHO NUMBER 11913

SCS